Results 71 to 80 of about 31,417,423 (292)

Physiologically based pharmacokinetic modeling of POPs in Greenlanders

Environment International, 2014
Human exposure to persistent organic pollutants (POPs) and the potential health impact in the Arctic far from the emission sources have been highlighted in numerous studies. As a supplement to human POP biomonitoring studies, a physiologically based pharmacokinetic (PBPK) model was set up to estimate the fate of POPs in Greenlandic Inuit's liver, blood,
Christian Sonne, Kim Gustavson, Frank F. Rigét, Rune Dietz, Tanja Krüger, Eva C. Bonefeld-Jørgensen   +5 more
openaire   +3 more sources

Engineering Concentration‐Dependent Intravitreal Mobility via Cyclic Arginine‐Enriched Nanocarrier Surface Modification: In Vivo Proof‐of‐Concept in a Porcine Large Animal Model

Advanced Healthcare Materials, EarlyView.
In this study, Hammer et al. highlight cyclic‐arginine surface engineering as a highly biocompatible, controllable, and concentration‐dependent regulator of intravitreal nanoparticle mobility in vivo in a translational large animal model. The cyclic arginine surface‐modification supports the development of next‐generation biomaterials for long‐acting ...
Maximilian Hammer, Bryan Calder Ackermann, Anna Stoß, Niklas Junker, Ludwig Geisweid, Sabrina Wohlfart, Jonathan Herth, Simon William Pohl, Manuel Ben Böhmann, André Schulz, Victor Aristide Augustin, Gerd Uwe Auffarth, Philipp Uhl   +12 more
wiley   +1 more source

A physiologically‐based pharmacokinetic model for tuberculosis drug disposition at extrapulmonary sites

CPT: Pharmacometrics & Systems Pharmacology, 2023
Tuberculosis (TB) is a leading cause of mortality attributed to an infectious agent. TB primarily targets the lungs, but in about 16% cases can affect other organs as well, giving rise to extrapulmonary TB (EPTB).
Aparna Ramachandran, Chetan J. Gadgil
doaj   +1 more source

Genome-Wide Gene Expression Analysis in Response to Organophosphorus Pesticide Chlorpyrifos and Diazion in C.Elegans [PDF]

, 2010
pesticides (OPs) were originally designed to affect the nervous system by inhibiting the enzyme acetylcholinesterase, an important regulator of the neurotransmitter acetylcholine.
Kammenga Jan E., Joost A. G. Riksen, Riksen Joost A. G., Ana Viñuela, L Basten Snoek, Viñuela Ana, Jan E. Kammenga, Joost A G Riksen, Kammenga, J.E., Snoek, L.B., L. Basten Snoek, Viñuela Rodriguez, A., Jan E Kammenga, Snoek L. Basten, Riksen, J.A.G.   +14 more
core   +1 more source

From Cell‐Derived Vesicles to Hybrid Nanovectors: Biological Membranes as Functional Blueprints for Gene Delivery

Advanced Healthcare Materials, EarlyView.
Biologically derived and hybrid nonviral nanovectors are examined as distinct but convergent design approaches. Integrating synthetic components with biologically functionalized membranes allows efficient interactions with complex cellular environments.
Clara Baldari, Claudia Leone, Gabriella Leccese, Claudia De Stradis, Alessandra Invidia, Concetta Quintarelli, Biagio De Angelis, Franco Locatelli, Giuseppe Gigli, Gabriele Maiorano, Ilaria Elena Palamà   +10 more
wiley   +1 more source

A physiologically-based pharmacokinetic model for the antibiotic ertapenem

Mathematical Biosciences and Engineering, 2016
Ertapenem is an antibiotic commonly used to treat a broad spectrum of infections, which is part of a broader class of antibiotics called carbapenem. Unlike other carbapenems, ertapenem has a longer half-life and thus only has to be administered once a day.
Michele L. Joyner, Cammey C. Manning, Whitney Forbes, Michelle Maiden, Ariel N. Nikas   +4 more
openaire   +5 more sources

Engineered Nanoplatforms Targeting Activated Hepatic Stellate Cells for Liver Fibrosis Therapy via TGF‐β Axis Inhibition and Ferroptosis Induction

Advanced Healthcare Materials, EarlyView.
FeS‐VA@lanifibranor (FVL), an activated hepatic stellate cell (aHSC)‐targeted nanoplatform comprising vitamin A‐functionalized two‐dimensional iron sulfide nanosheets and lanifibranor, is engineered for precision therapy of liver fibrosis. FVL suppresses the TGF‐β signaling pathway by inhibiting SMAD2/3 phosphorylation and induces ferroptosis in aHSCs,
Yinuo Yang, Mengyao Mu, Ke Ren, Hui Liu, Pengju Ma, Yingqi Wang, Mengmeng Zhang, Xueli Xu, Wenzhe Li, Wenshuang Gao, Xiao Sun, Qiang Zhu   +11 more
wiley   +1 more source

Physiologically based pharmacokinetic (PBPK) model fit and validation.

, 2019
Physiologically based pharmacokinetic (PBPK) model simulations (lines) and experimental blood plasma profile (circles) of IFN-α in humans. A) Experimental results of Wills et al. [36] and the corresponding fit.
Jörg Lippert (124210), Julian Brandl (3840103), Sven Sahle (222858), Lars Küpfer (6331121), Priyata Kalra (6331118), Christoph Niederalt (535381), Ursula Kummer (437648), Thomas Gaub (223638)   +7 more
core   +1 more source

2‐Deoxyglucose Dendrimer‐Enabled Niclosamide Delivery to FRβ‐Expressing Macrophages Alleviates Endometriosis Progression and Associated Hyperalgesia

Advanced Healthcare Materials, EarlyView.
A folic acid (FA)‐conjugated 2‐deoxyglucose dendrimer selectively targets FRβ+ macrophages in endometriotic lesions, enabling precise intracellular delivery of niclosamide. This nonhormonal nanomedicine enhances drug solubility, provides controlled intracellular release, suppresses lesion growth, reduces inflammation and pain, and establishes FRβ ...
Anubhav Dhull, Mingxin Shi, Madeleine E. Harvey, Taylor M. Page, Rishi Sharma, Kenneth John Goody, Aqib Iqbal Dar, Nash S. Moawad, Vijay Kumar Sirohi, Paul S. Cooke, Kanako Hayashi, Anjali Sharma   +11 more
wiley   +1 more source

Physiologically-Based Pharmacokinetic Model for Ertapenem [PDF]

, 2014
Ertapenem is a carbapenem used to treat a wide range of bacterial infections. What sets ertapenem apart from other carbapenems is its longer half-life which implies it need only be administered once daily.
Forbes, Whitney
core   +1 more source